Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
Open Access
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (8) , 1097-1106
- https://doi.org/10.1023/a:1011663821703
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation studyAnnals of Oncology, 1999
- EpirubicinDrugs, 1997
- Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.Journal of Clinical Oncology, 1996
- Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.Journal of Clinical Oncology, 1993
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensBritish Journal of Cancer, 1993
- Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic StudiesPharmaceutical Research, 1992
- New Cytotoxic Drugs in Treatment of Breast CancerActa Oncologica, 1990
- Reporting results of cancer treatmentCancer, 1981
- Clinical Evaluation of Adriamycin, a New Antitumour AntibioticBMJ, 1969